Answers are grounded in this paper and cite their sources.
Objectives. To investigate the prevalence of neuropathic pain symptoms and to analyze the correlation between neuropathic symptoms with pain‐related, psychological, and cognitive variables in COVID‐19 survivors exhibiting “de novo” post‐COVID pain. Methods. Seventy‐seven (n = 77) previously hospitalized COVID‐19 survivors presenting with post‐COVID pain completed demographic (such as age, height, and weight), pain‐related (the duration and intensity of pain), psychological (depressive/anxiety levels), and cognitive (catastrophizing and kinesiophobia) variables. The Self‐Report Leeds Assessment of Neuropathic Symptoms and Signs (S‐LANSS) questionnaire was also assessed. After conducting multivariable correlation analyses, a stepwise multiple linear regression model was performed to identify S‐LANSS predictors. Results. Participants were assessed a mean of 6.0 (SD 0.8) months after hospital discharge. Nineteen (24.6%) exhibited neuropathic pain symptoms (S‐LANSS score≥12 points). The S‐LANSS score was positively associated with the duration of post‐COVID pain (r: 0.262), anxiety levels (r: 0.275), and kinesiophobia level (r: 0.291) (all, P < 0.05). The stepwise regression analysis revealed that 12.8% of the S‐LANSS variance was just explained by kinesiophobia. Conclusion. This study found that almost 25% of previously hospitalized COVID‐19 survivors with “de novo” post‐COVID pain reported a neuropathic pain component. The presence of neuropathic pain symptomatology was associated with more anxiety and kinesiophobia, but only kinesiophobia level was significantly associated explaining 12.8% of the variance of the S‐LANSS score.
No takes yet. Share an insight, caveat, or question.
Herrero‐Montes et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: